AAX Biotech is developing new technologies to improve antibodies for therapy, the fastest growing segment in pharmaceuticals for more than 20 years. Seqitope is a new high-resolution, fast and efficient method for determining exactly where antibodies bind to the target protein, which accelerates the development of new antibodies. With Opti-mAb, we have developed a general method to stabilize antibodies, of great value in new cell-based cancer treatments such as CAR-T, but also for therapeutic bi-specific antibodies, and in diagnostics. In addition, a more efficient production, a more homogeneous product and fewer side effects are obtained during clinical use.
We are part of KI Innovations Incubator/Accelerator DRIVE.
Milestones titleThis text is hidden in the job ads. Edit the title from the field above.
Lorem ipsumFusce volutpat consequat velit, sed scelerisque lorem egestas a. Vestibulum ut odio sagittis, aliquam sapien a, pulvinar nisi. Lorem ipsum dolor sit amet, consectetur adipiscing elit.
Lorem ipsumLorem ipsum dolor sit amet, consectetur adipiscing elit. Etiam lobortis libero sed malesuada dictum. Fusce volutpat consequat velit, sed scelerisque lorem egestas a.
Lorem ipsumVestibulum ut odio sagittis, aliquam sapien a, pulvinar nisi. Lorem ipsum dolor sit amet, consectetur adipiscing elit.
Available Jobs
Great Place to Work
Maecenas blandit, tortor sed finibus
Est metus eleifend justo
In facilisis nunc ac lectus fermentum
Quisque ultrices blandit quam
Aenean interdum nisl vitae justo
Praesent tincidunt vitae nisi et rhoncus
